Detection, clinical relevance and specific biological properties of disseminating tumour cells

Most cancer deaths are caused by haematogenous metastatic spread and subsequent growth of tumour cells at distant organs. Disseminating tumour cells present in the peripheral blood and bone marrow can now be detected and characterized at the single-cell level. These cells are highly relevant to the study of the biology of early metastatic spread and provide a diagnostic source in patients with overt metastases. Here we review the evidence that disseminating tumour cells have a variety of uses for understanding tumour biology and improving cancer treatment.

[1]  H. A. Bakker,et al.  Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. , 1996, The American journal of pathology.

[2]  T. Fehm,et al.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status , 2007, Breast Cancer Research.

[3]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[4]  M. Rezai,et al.  Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients , 2007 .

[5]  M. Speicher,et al.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[7]  S. Braun,et al.  Tumor–antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease , 1999, International journal of cancer.

[8]  R. Eils,et al.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.

[9]  H. Kalthoff,et al.  Detection and clinical implications of minimal residual disease in gastro-intestinal cancer , 2005, Langenbeck's Archives of Surgery.

[10]  Veit Zieglschmid,et al.  Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. , 2005, Anticancer research.

[11]  L. Weiner,et al.  Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. , 2006, Clinical colorectal cancer.

[12]  J. Mendelsohn,et al.  Circulating tumor cells in breast cancer: Advanced tools for “tailored” therapy? , 2006, Proceedings of the National Academy of Sciences.

[13]  S. Loibl,et al.  Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro , 2007 .

[14]  S. Braun,et al.  The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence , 2005, Cancer.

[15]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Wicha.  Cancer Stem Cells and Metastasis: Lethal Seeds , 2006, Clinical Cancer Research.

[17]  D. Mavroudis,et al.  Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Semjonow,et al.  Frequent Detection and Immunophenotyping of Prostate-Derived Cell Clusters in the Peripheral Blood of Prostate Cancer Patients , 2004, The International journal of biological markers.

[19]  M. Menon,et al.  Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine , 2007, Proceedings of the National Academy of Sciences.

[20]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Nesland,et al.  Immunocytochemical detection of isolated epithelial cells in bone marrow: non‐specific staining and contribution by plasma cells directly reactive to alkaline phosphatase , 1998, The Journal of pathology.

[22]  Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.

[23]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Yie,et al.  Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA , 2006, Clinical & Experimental Metastasis.

[25]  Sanjay Shete,et al.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.

[26]  D. Mavroudis,et al.  Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. , 2006, Clinical biochemistry.

[27]  P. Paterlini-Bréchot,et al.  Circulating tumor cells (CTC) detection: clinical impact and future directions. , 2007, Cancer letters.

[28]  Tania Nolan,et al.  Quantification of mRNA using real-time RT-PCR , 2006, Nature Protocols.

[29]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[30]  H. Allgayer,et al.  Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Cristofanilli.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2006, Seminars in oncology.

[32]  K. Hunter,et al.  Host genetics influence tumour metastasis , 2006, Nature Reviews Cancer.

[33]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[34]  J. Nesland,et al.  Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.

[35]  Mario Pazzagli,et al.  Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. , 2006, Human pathology.

[36]  L. Sobin,et al.  Classification of isolated tumor cells , 2003, Cancer.

[37]  S. Braun,et al.  Biological Characteristics of Micrometastatic Cancer Cells in Bone Marrow , 1999, Cancer and Metastasis Reviews.

[38]  C. Jackisch,et al.  Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. , 1998, The American journal of pathology.

[39]  P. Platzer,et al.  Breast-cancer stromal cells with TP53 mutations and nodal metastases. , 2007, The New England journal of medicine.

[40]  C. Sotiriou,et al.  Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Ruud H. Brakenhoff,et al.  Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.

[42]  J. Uhr.  Cancer diagnostics: One-stop shop , 2007, Nature.

[43]  J. Thiery,et al.  Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer , 2003, British Journal of Cancer.

[44]  G. Snow,et al.  Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  Siyang Zheng,et al.  Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. , 2007, Journal of chromatography. A.

[46]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[47]  E. van Marck,et al.  Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time , 2006, Clinical chemistry and laboratory medicine.

[48]  D. Mavroudis,et al.  Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  T. Fehm,et al.  Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy , 2006, Breast Cancer Research and Treatment.

[50]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[51]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[52]  J. Pierga,et al.  Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  S. Braun,et al.  ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. , 2001, Cancer research.

[54]  L. Kiesel,et al.  HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.

[55]  Peter Kuhn,et al.  A rare-cell detector for cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Godfrey,et al.  Development of quantitative reverse transcriptase PCR assays for measuring gene expression. , 2005, Methods in molecular biology.

[57]  H. Ju,et al.  Circulating Tumor Cells in Perioperative Esophageal Cancer Patients: Quantitative Assay System and Potential Clinical Utility , 2007, Clinical Cancer Research.

[58]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[59]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[60]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[61]  J. Chang,et al.  Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2007 .

[62]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[64]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Jaw-Yuan Wang,et al.  Molecular Detection of Circulating Tumor Cells in the Peripheral Blood of Patients with Colorectal Cancer Using RT-PCR: Significance of the Prediction of Postoperative Metastasis , 2006, World Journal of Surgery.

[66]  T. Fehm,et al.  Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients , 2007, Breast Cancer Research and Treatment.

[67]  T. Hinterleitner,et al.  Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients. , 2005, The Journal of molecular diagnostics : JMD.

[68]  G. Assmann,et al.  c‐erbB‐2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  M J O'Hare,et al.  Linking gene expression patterns to therapeutic groups in breast cancer. , 2000, Cancer research.

[70]  Sabine Riethdorf,et al.  Detection and characterization of putative metastatic precursor cells in cancer patients. , 2007, Clinical chemistry.

[71]  H. Scher,et al.  Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[72]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[73]  Ton Feuth,et al.  Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes , 2005, Laboratory Investigation.

[74]  K. Pantel,et al.  The clinical significance of circulating tumor cells , 2007, Nature Clinical Practice Oncology.

[75]  Jaw-Yuan Wang,et al.  Multiple Molecular Markers as Predictors of Colorectal Cancer in Patients with Normal Perioperative Serum Carcinoembryonic Antigen Levels , 2007, Clinical Cancer Research.

[76]  G. Jiang,et al.  CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. , 2007, Lung cancer.

[77]  T. Fehm,et al.  A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.

[78]  E. Diamandis,et al.  Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications , 2002 .

[79]  J. Köllermann,et al.  Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Philip S Low,et al.  In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry , 2007, Proceedings of the National Academy of Sciences.

[81]  C. R. Leemans,et al.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. , 2003, Cancer research.

[82]  T. Fehm,et al.  Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer , 2006, Breast Cancer Research.

[83]  S. Agelaki,et al.  Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  Jaw-Yuan Wang,et al.  Development of a high‐throughput membrane‐array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers , 2006, International journal of cancer.

[85]  E. Kubista,et al.  Circulating breast cancer cells are frequently apoptotic. , 2001, The American journal of pathology.

[86]  Joe W Gray,et al.  Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. , 2003, Cancer cell.

[87]  K. Pantel,et al.  Current status in human breast cancer micrometastasis , 2007, Current opinion in oncology.

[88]  Michael Baum,et al.  Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures , 2007, Nature Clinical Practice Oncology.

[89]  R. Brakenhoff,et al.  Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  H. Graham,et al.  Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years , 2005, International journal of cancer.

[91]  J. García,et al.  Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients , 2007, Breast Cancer Research.

[92]  A. Semjonow,et al.  Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. , 2006, Cancer research.

[93]  L. Ylagan,et al.  Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 as a Marker of Early Tumor Relapse in Breast Cancer Patients , 2007, Clinical Cancer Research.

[94]  T. Godfrey,et al.  Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. , 2007, Clinical chemistry.

[95]  A. Jimeno,et al.  Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  T. Fehm,et al.  Persistence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients predicts increased risk for relapse-Results of pooled European data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[98]  Leon W.M.M. Terstappen,et al.  Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[99]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[100]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.

[101]  R. Crevoisier,et al.  High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  J. Pierga,et al.  Detection of MUC 1-expressing Mammary Carcinoma Cells in the Peripheral Blood of Breast Cancer Patients by Real-Time Polymerase Chain Reaction 1 , 2000 .

[104]  R. Gangnus,et al.  Genomic Profiling of Viable and Proliferative Micrometastatic Cells from Early-Stage Breast Cancer Patients , 2004, Clinical Cancer Research.

[105]  L. Sobin,et al.  How to improve the present TNM staging system , 1999, Cancer.

[106]  K. Pittman,et al.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction , 1991, The Lancet.

[107]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[108]  J. Nesland,et al.  Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.

[109]  A. Adjei,et al.  Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor , 2007, Clinical Cancer Research.

[110]  R. Coombes,et al.  The clinical significance of disseminated tumor cells in breast cancer , 2007, Nature Clinical Practice Oncology.

[111]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[112]  G Kvalheim,et al.  Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. , 1999, Cytotherapy.

[113]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[114]  Peter Kuhn,et al.  High speed detection of circulating tumor cells. , 2006, Biosensors & bioelectronics.

[115]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[116]  D. Kwiatkowski,et al.  Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[118]  D. Wallwiener,et al.  Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  P. Schneider,et al.  Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers , 2007, Journal of surgical oncology.

[120]  Robert A. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer (Nature (2007) 449, (682-688)) , 2008 .

[121]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[122]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[124]  H. Kalthoff,et al.  Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival , 2005, Journal of Cancer Research and Clinical Oncology.

[125]  Anne Vincent-Salomon,et al.  Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.

[126]  N. Stoecklein,et al.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.

[127]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[128]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[129]  P. Kober,et al.  The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. , 2006, European journal of cancer.

[130]  G. Assmann,et al.  Isolation of blood‐borne epithelium‐derived c‐erbB‐2 oncoprotein‐positive clustered cells from the peripheral blood of breast cancer patients , 1998, International journal of cancer.

[131]  P. Platzer,et al.  Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. , 2007, JAMA.

[132]  W. J. Allard,et al.  Circulating tumor cells predict survival in patients with metastatic prostate cancer. , 2005, Urology.

[133]  K. Pienta,et al.  Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.